American Heart Journal
Volume 141, Issue 6 , Pages 908-914 , June 2001

Hemodynamics as surrogate end points for survival in advanced heart failure: An analysis from FIRST

Received 11 August 2000 ,Accepted 16 February 2001.

References 

  1. Packer M. Vasodilator and inotropic drugs for chronic heart failure: distinguishing hype from hope. J Am Coll Cardiol. 1988;12:1299–1317
  2. Psaty BM, Weiss NS, Furberg CD, et al.  Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease. JAMA. 1999;282:786–795
  3. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled?. Ann Intern Med. 1996;125:605–613
  4. Lipicky RJ, Packer M. Role of surrogate end points in the evaluation of drugs for heart failure. J Am Coll Cardiol. 1993;22:179A-84A
  5. Wittes J, Lakatos E, Probstfield J. Surrogate end points in clinical trials: cardiovascular diseases. Stat Med. 1989;8:415–425
  6. Prentice RL. Surrogate end points in clinical trials: definition and operational criteria. Stat Med. 1989;8:431–440
  7. Cohn JN, Goldstein SO, Greenberg BH, et al.  A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. for the VESnarinone Trial Investigators N Engl J Med. 1998;339:1810–1816
  8. Packer M, Carver JR, Rodeheffer RJ, et al.  Effect of oral milrinone on mortality in severe chronic heart failure. for the PROMISE Study Research Group N Engl J Med. 1991;325:1468–1475
  9. Stevenson LW, Sietsema K, Tillisch JH, et al.  Exercise capacity for survivors of cardiac transplantation or sustained medical therapy for stable heart failure. Circulation. 1990;81:78–85
  10. Fonarow GC, Stevenson LW, Walden JA, et al.  Impact of a comprehensive heart failure management program on hospital readmission and functional status of patients with advanced heart failure. J Am Coll Cardiol. 1997;30:725–732
  11. Hanamanthu S, Butler J, Chomsky D, et al.  Effect of a heart failure program on hospitalization frequency and exercise tolerance. Circulation. 1997;96:2842–2848
  12. Califf RM, Adams KF, McKenna WJ, et al.  A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST). Am Heart J. 1997;134:44–54
  13. Gheorghiade M. OPTIME-CHF preliminary results. Presented at the 49th Annual Scientific Session of the American College of Cardiology, March 12 to 15, 2000, Anaheim, Calif.
  14. Packer M, Rouleau J, Swedberg K, et al.  Effect of flosequinan on survival in chronic heart failure: preliminary results of the PROFILE study. Circulation. 1993;88(suppl I):I-301
  15. Franciosa JA, Cohn JN. Effects of minoxidil on hemodynamics in patients with congestive heart failure. Circulation. 1981;63:652–657
  16. Franciosa JA, Jordan RA, Wilen MM, et al.  Minoxidil in patients with left heart failure: contrasting hemodynamic and clinical effects in a controlled trial. Circulation. 1984;70:63–69
  17. Elkayam U, Amin J, Mehra A, et al.  A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy to isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. Circulation. 1990;82:1954–1961
  18. Fonarow GC, Chelimsky-Fallick C, Stevenson LW, et al.  Effect of direct vasodilation with hydralazine versus angiotensin-converting enzyme inhibition with captopril on mortality in advanced heart failure: the Hy-C trial. J Am Coll Cardiol. 1992;19:842–850
  19. MERIT-HF Study Group . Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet. 1999;353:2001–2007
  20. CIBIS-II Investigators and Committees . The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9–13
  21. Johnson W, Lucas C, Stevenson LW, et al.  Effect of intensive therapy for heart failure on the vasodilator response to exercise. J Am Coll Cardiol. 1999;33:743–749
  22. Chomsky DB, Lang CC, Rayos G, et al.  Treatment of subclinical fluid retention in patients with symptomatic heart failure: effect on exercise performance. J Heart Lung Transplant. 1997;16:846–853
  23. Stevenson LW, Massie BM, Francis GS. Optimizing therapy for complex or refractory heart failure: a management algorithm. Am Heart J. 1998;135:S293–S309

☆ Supported in part by Glaxo-Wellcome, Research Triangle Park, NC.

☆☆ Reprint requests: Monica R. Shah, MD, Duke Clinical Research Institute, PO Box 17969, Durham, NC 27715. E-mail: shah0013@mc.duke.edu

★ Guest Editor for this manuscript was Robert O. Bonow, MD, Northwestern University Medical School, Chicago, Ill.

PII: S0002-8703(01)70016-6

doi: 10.1067/mhj.2001.115299

American Heart Journal
Volume 141, Issue 6 , Pages 908-914 , June 2001

Article Tools

* Image Usage & Resolution